332
D
Delaying surgery, 132
Demyelinating disease, 249, 251, 253
Drug and antidrug antibody assays, 316
E
Eczematiform lesions
clinical presentation, 238
diagnosis, 241
management, 242
risk factors, 238, 239
Electrochemiluminescence immunoassay
(ECLIA) assay, 118, 119
Enzyme-linked immunosorbent assays
(ELISA), 115, 116, 118, 119
Ertrolizumab, phase II randomized controlled
trial, 305
Erythema nodosum (EN), 53
Etrolizumab (rhuMAb β7), 294, 295, 304
Extraintestinal manifestations (EIM)
adalimumab, 49
certolizumab pegol, 49
golimumab, 49
infliximab, 49
Extrapolation, 270–272
F
Fecal calprotectin (fCal), 61
Fetal immunity, 83
Filgotinib, 304, 310
Fluid-phase-based radioactive immunoassay,
119
G
Genome-wide association studies, 186
Golimumab, 18, 23, 24
UC
antidrug antibody formation, 23
induction and maintenance clinical
trial, 18, 23
long-term safety and efficacy data, 24
maintenance therapy, 23
tolerence, 23
H
Harvey Bradshaw (HB) index, 164
Heart failure, 253–255
Hepatosplenic T-cell lymphoma (HSTCL),
220, 221
Hepatotoxicity
clinical presentation, 246, 247
diagnosis, 248
management, 249
pathophysiology, 248
prognosis, 248
risk factors, 247
High-pressure liquid chromatography
mobility shift assay (HMSA),
118, 119, 121
Hodgkin’s lymphoma, 219I
IBD-associated peripheral arthritis, 50
Immune reconstitution syndrome, 287
Immunogenicity, 114, 115
Immuno-inflammatory pathways, 296
Immuno-pathogenesis, 283
Immunosuppressive therapy, 101–108, 131,
132, 224, 225
complications, prevention
limitations, 225
primary, 224
secondary, 224
skin screening examinations, 224
tertiary, 224
medications, 131
population-based studies, 225
risk factors, 215
TNF-antagonists
adalimumab, 102
azathioprine, 103
clinical algorithm, 107
comparative effectiveness studies, 108
disease related complications,
103, 107, 108
high-dose steroid induction, 101
immune pathway-specific biologics,
108
infliximab, 103
malignancy development, 105
monotherapy, 108
optimization, 105, 106
pharmacokinetics, 103
randomized controlled trials, 101, 102
REACT trial, 103
safety, 104
stratified analysis, 102
thiopurine monotherapy, 107
treatment personalization, 108
treatment-related serious infections,
104, 105Index